INS and myocardial infarction: DIGAMI‐2 is a double‐blind, prospective RCT that randomized 1253 patients with myocardial infarction and an established type II diabetes to receiving either 24 h insulinglucose infusion followed by a subcutaneous insulin‐based long‐ term glucose control (Group 1), 24 h insulin–glucose infusion followed by standard glucose control (Group 2) or routine metabolic management according to local practice (Group 3).